|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
No data available.
AC Immune (ACIU)
Trading: BUY @ $6.64
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has been constructed to highlight the existence of a trend for an assocaited timeframe. Trend determining indicators can be used in short, medium or long term timeframes & determines if the stock is trending or ranging. Once the trend status is quantified, this can then be coupled to additional indicators to add a significant advantage to the trading strategy.
AC Immune (NASDAQ:ACIU) has a current Supertrend of 4.561. This has change 0 points from yesterday.
The Supertrend is a trend following indicator which identifies uptrends and downtrends. The SuperTrend indicator is calculated utilising the ATR to offset the indicator from the common price. Before understanding the supertrend indicator, understanding the ATR is essential as super trend employs ATR values to calculate the indicator values. This indicator fluctuates above and below 0 signalling the current direction of the trend. This is a lagging trend indicator that assists in defining trend directions does not perform well in ranging markets.
Calculation: Supertrend (SUP) :
1) Basic Upper band = (High + Low) / 2 + Multiplier * ATR;
2) Basic Lower band = (High + Low) / 2 - Multiplier * ATR
3) Final Upper band = IF((Basic Upper band < Final Upper band(yest)) OR (Close(yest) > Previous Final Upper band(yest))) THEN (Basic Upper band) ELSE Final Upper band(yest));
4) Final Lower band = IF((Basic Lower band > Final Lowerband (yest)) OR (Close(yest) < Final Lower band(yest))) THEN (Basic Lower band) ELSE Final Lower band(yest));
5) Supertrend = IF(Close <= Final Upper band ) THEN Final Upper band ELSE Final Lower band;
Where Multiplier = 3; Period=14
PROFILE: AC Immune (ACIU)
Stock Exchange: NASDAQ
Company: AC Immune
Ticker Codes: | ACIU | NASDAQ:ACIU |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Essex Bio-Technology Limited, as well as NestlÚ Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
|GPP Green Plains Partners||6.26||17.7||74,503||-0.65||BULLISH|
|INO Inovio Pharma||8.17||14.3||26,189,397||-4.19||BULLISH|
|RVNC Revance Therapeutics||16.48||8.2||717,681||-2.06||BULLISH|
|ANGI Angie'S List Inc||5.34||7.7||1,758,757||-0.7||BULLISH|
|PRTK Paratek Pharma||3.42||7.2||427,643||-0.39||BULLISH|
|MCRB Seres Theraptc||3.74||6.9||75,031||1.39||BULLISH|